Is TG Therapeutics, Inc. (TGTX) a Buy, Sell, or Hold?
TG Therapeutics, Inc.
NASDAQ:TGTX
$56.41 USD
$1.52 (2.77%)
- Volume
- 1.6M
- Average Volume
- 2.4M
- Market Capitalization
- $8.64B
- P/E Ratio
- 17.74
- Dividend Yield
- 0.00%
- Price Target
- $76.50
- Year High
- $59.30
- Year Low
- $25.28
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.81
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Michael S. Weiss |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | TGTX |
| CUSIP | 88322Q108 |
| CIK | 0001001316 |
| Web | https://www.tgtherapeutics.com |
| Phone | 212 554 4484 |
| Currency | USD |
| Employees | 399 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 1.29 |
| Payout Ratio | 0.00 |
| Current Ratio | 5.81 |
| Quick Ratio | 5.12 |
| Cash Ratio | 2.36 |
Sales & Book Value
| Annual Sales | $616.29M |
| Price / Sales | 12.33 |
| Cash Flow | -0.10 |
| Price / Cash Flow | -608.52 |
| Price / Book | 13.97 |
Price Target and Rating
| Average Stock Price Forecast | $76.50 |
| High Stock Price Forecast | $83.00 |
| Low Stock Price Forecast | $70.00 |
| Forecast Upside/Downside | -26.26% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 13 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $2.77 |
| Trailing P/E Ratio | 17.74 |
| PEG Ratio | 0.02 |
| P/E Growth | 0.02 |
| Net Income | $447.18M |
| Net Margin | 65.95% |
| Pretax Margin | 17.46% |
| Return on Equity | 87.36% |
| Return on Assets | 30.21% |
Financials Score
| AltmanZ Score | 5.85 |
| Piotroski Score | 4.00 |
| Working Capital | 899.86M |
| Total Assets | 1.53B |
| Ebit | 149.92M |
| Market Cap | 8.4B |
| Total Liabilities | 945.71M |
Poll Results
About TG Therapeutics, Inc. (NASDAQ:TGTX) Stock
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treat ... ment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.
2 Fast-Growing Pharmaceutical Stocks to Buy Now
2026-07-08 20:05:00
Incyte and TG Therapeutics are seeing strong share growth, backed up by booming revenue and earnings.
TG Therapeutics Begins Phase II Study With Briumvi in Schizophrenia
2026-07-07 10:01:28
TGTX initiates a phase II study evaluating Briumvi in adult patients with treatment-resistant schizophrenia. Shares rise.
2026-07-06 07:30:00
Phase 2 trial to evaluate the effects of B-cell depletion with BRIUMVI in approximately 60 patients with treatment-resistant schizophrenia based on emerging evidence linking immune dysfunction to disease in a subset of patients Phase 2 trial to evaluate the effects of B-cell depletion with BRIUMVI in approximately 60 patients with treatment-resistant schizophrenia based on emerging evidence linking immune dysfunction to disease in a subset of patients
Will Briumvi's Strength Continue to Aid TGTX's Top Line in Q2?
2026-07-03 09:55:45
TG Therapeutics continues to witness rising Briumvi demand. Investors are closely watching the sales numbers of the drug.
TG Therapeutics Stock Rises Thursday: What's Driving The Gains?
2026-06-18 15:29:40
TG Therapeutics Inc. (NASDAQ:TGTX) shares are trading higher on Thursday as traders keep leaning into recent upbeat clinical updates around BRIUMVI.
TG Therapeutics Stock Is On A Hot Streak: Why It's Up 70% And Climbing
2026-06-17 08:00:03
TG Therapeutics stock is on an absolute rampage, climbing 70% in roughly the first six months of the year, as the biotech takes on Roche.
TG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock?
2026-06-11 06:16:07
TG Therapeutics (TGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
TGTX Rises on Positive Phase I Data for Subcutaneous Briumvi in MG
2026-06-10 10:21:05
TG Therapeutics gains after positive phase I data for subcutaneous Briumvi in myasthenia gravis or MG, while a phase II study in MG gets underway.
Frequently Asked Questions
-
What is the current TG Therapeutics, Inc. (TGTX) stock price?
-
TG Therapeutics, Inc.(NASDAQ:TGTX) stock price is $56.41 in the last trading session. During the trading session, TGTX stock reached the peak price of $59.3 while $25.28 was the lowest point it dropped to. The percentage change in TGTX stock occurred in the recent session was 2.77% while the dollar amount for the price change in TGTX stock was $1.52.
-
TGTX's industry and sector of operation?
-
The NASDAQ listed TGTX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of TGTX?
-
Michael S. Weiss | Chairman, Chief Executive Officer & President
Adam Waldman | Chief Commercialization Officer
Jenna Bosco | Senior Vice President of Corporate Communications
Sean A. Power | Chief Financial Officer, Corporate Secretary & Treasurer
| -
How many employees does TGTX have?
-
Number of TGTX employees currently stands at 399. TGTX operates from 2 Gansevoort Street, Morrisville, NY 10014, US.
-
Link for TGTX official website?
-
Official Website of TGTX is: https://www.tgtherapeutics.com
-
How do I contact TGTX?
-
TGTX could be contacted at phone #212 554 4484 and can also be accessed through its website. TGTX operates from 2 Gansevoort Street, Morrisville, NY 10014, US.
-
How many shares of TGTX are traded daily?
-
The average number of TGTX shares traded daily for last 3 months was 2.4M.
-
What is the market cap of TGTX currently?
-
The market value of TGTX currently stands at $8.64B with its latest stock price at $56.41